The Ministry of Health and Prevention along with the Department of Health in Abu Dhabi and Dubai Health Authority has announced the results from using Sotrovimab, the anti-viral treatment for COVID-19.
The medication was used to treat adults, pregnant women and children aged 12 and above that showed severe symptoms as well as meet other criteria for administration.
The medication was administered to 658 patients with COVID-19 from 16 June to 29 June.
46% were citizens, 54% were residents, with 59% of patients were aged 50 or above.
Within five to seven days, 97.3% of patients showed improvements with symptoms subsiding and making a full recovery.
Patients that were obese, have cancer, kidney diseases, lung diseases, cardiovascular diseases, diabetes, hypertension and allergies were in the risk categories where the medication was prescribed.
The UAE was one of the first countries in the world to receive the treatment after the Ministry of Health and Prevention approved the use of Sotrovimab.
The medication is produced by a global biopharmaceutical company, GlaxoSmithKline after local evaluations were held as well as approval for emergency use by the US Food and Drug Administration was received.